Enovis CORP (ENOV) stock
Close on Nov 13, 2026Market cap $1.60BP/E –Yield –
Enovis CORP grew revenue 3.3% to $2.31B over the twelve months to Oct 2, 2026. Free cash flow was $69.56M, up 205.6% from a year earlier. At the latest close the market valued the company at $1.60B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Oct 2, 2026
Valuation
- Market cap
- $1.60B
- P/E ratio
- –
- Price to sales
- 0.69
- Price to book
- 1.07
- Dividend yield
- –
- Free cash flow yield
- 4.36%
Fundamentals
- Revenue
- $2.31B
- Net income
- -$527.40M
- EPS, diluted
- -$9.21
- Free cash flow
- $69.56M
- Book value per share
- $25.53
- Diluted shares
- 58M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $27.64
- Open
- $28.65
- Day's range
- $27.63 – $28.89
- Volume
- 1,205,421
- Average volume (20 days)
- 1,866,680
- Index membership
- S&P SmallCap 600 (since Feb 2025), Russell 2000 (since Jun 2025), Russell 3000 (since May 2022)
- Beta (5 years)
- 1.14
- 52-week range
- $16.70 – $31.81
- RSI (14 days)
- 66.7
- Volatility (1 year)
- 68.3%
- Relative volume
- 0.78×
- WACC
- 7.8%
On 2 of our idea lists: Insider cluster buys, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ENOV | S&P 500 | Difference | ENOV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +45.8% | -3.0% | +48.8 pts | ||
| 3 months | +7.9% | -2.8% | +10.7 pts | ||
| Year to date | +3.9% | +11.5% | −7.6 pts | ||
| 1 year | -10.3% | +13.5% | −23.8 pts | ||
| 3 years | -42.6% | +77.7% | −120.3 pts | -16.9% | +21.1% |
| 5 years | -82.2% | +72.6% | −154.9 pts | -29.2% | +11.5% |
| 10 years | -74.6% | +308.2% | −382.8 pts | -12.8% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Enovis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Results
About Enovis
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Enovis Corporation is a medical technology company that develops, manufactures, and distributes medical devices across the care continuum, from injury prevention to joint replacement and post-operative rehabilitation. The company operates through two segments: Prevention & Recovery, and Reconstructive. The Prevention & Recovery segment provides orthopedic braces, temperature therapies, bone growth stimulators, compression garments, and pain management equipment. The Reconstructive segment supplies surgical implants, instrumentation, and digital planning technologies for joint replacement and limb reconstruction. Enovis serves orthopedic specialists, surgeons, physical therapists, healthcare systems, and retail consumers.
Company profile, executives and historyEnovis stock: common questions
What is Enovis's stock price?
ENOV closed at $27.68 on Nov 13, 2026, up 0.14% on the day. Over the past 52 weeks it traded between $16.70 and $31.81.
What is Enovis's market cap?
Enovis was worth $1.60B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ENOV's P/E ratio?
Enovis lost money over the twelve months to Oct 2, 2026 (diluted EPS -$9.21), so it has no meaningful P/E ratio.
How much revenue does Enovis make?
Enovis reported revenue of $2.31B for the twelve months to Oct 2, 2026, up 3.3% from a year earlier.
Does Enovis pay a dividend?
No. Enovis has not paid a cash dividend over the last twelve months.
When does Enovis report earnings next?
Enovis is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ENOV stock performed over the past year?
Including dividends, ENOV returned -10.3% over the past year, against +13.5% for the S&P 500.
How many ENOV shares are sold short?
11M shares were sold short at the latest FINRA report, 18.81% of the float, or 7.3 days of average trading volume.
Who are Enovis's competitors?
Companies most similar to Enovis by business, industry and size include SNN, MSA, GMED, CNMD, IART.
See a number that looks wrong?